CBD for Dogs: What Current Veterinary Research Can and Cannot Tell Us
Last reviewed · Citation policy
The evidence on CBD for dogs is mixed and still limited. What peer-reviewed research says about safety, efficacy, drug interactions, and quality — and how to opt out of CBD product recommendations.
Published
2022
Updated
Apr 10, 2026
References
6 selected
Pharmacology and botanical classification
CBD (cannabidiol) is one of over a hundred phytocannabinoids found in Cannabis sativa. Unlike delta-9-tetrahydrocannabinol (THC), CBD does not produce psychoactive intoxication. In the pet supplement market, CBD is almost always derived from industrial hemp. Under the 2018 Farm Bill, hemp is legally defined as containing no more than 0.3% delta-9 THC on a dry weight basis.
The main mechanism of interest is the endocannabinoid system (ECS), a lipid-signaling network present in all mammals. It includes CB1 receptors (mainly in the brain) and CB2 receptors (mainly in immune tissue). CBD does not directly activate CB1 like THC does. Instead, it acts as a negative allosteric modulator of CB1 and also interacts with serotonin 5-HT1A receptors and TRPV1 channels. How these actions affect anxiety in dogs is still being studied.
CBD is not a synonym for hemp
This distinction matters for both regulation and clinical use. Many products labeled "hemp" actually contain only hemp seed oil or hemp powder. These have almost no CBD. Hemp seed products fall under a different regulatory category than CBD extracts made from the flowers and leaves of the plant. If a product does not list cannabidiol content in milligrams per serving, it is almost certainly a hemp-seed product rather than a true CBD formulation. Products labeled "hemp extract" or "whole-plant extract" may still contain cannabinoids and should come with a Certificate of Analysis (COA). See the dedicated hemp vs. CBD guide for a full breakdown.
Key takeaway
CBD is a specific phytocannabinoid. It works through ECS modulation, 5-HT1A receptors, and TRPV1 channels. It is not the same as hemp seed oil and is not psychoactive like THC. Under the 2018 Farm Bill, legal hemp must contain no more than 0.3% delta-9 THC by dry weight.
Clinical evidence review: safety and behavioral efficacy
Honest summary of the current literature: short-term safety looks reasonable in the studies we have. Behavioral efficacy evidence is much thinner, more variable in quality, and harder to generalize than marketing often claims.
Safety and tolerability
Generally favorable in short-term studies; hepatic enzyme elevation is a consistent finding.
Di Salvo et al. (2023) noted that most canine CBD safety data comes from just four osteoarthritis trials. In short-term use (2–12 weeks), dogs generally tolerated oral CBD well. The most common side effects were mild gastrointestinal issues such as soft stool and temporary appetite loss. However, several studies consistently found dose-dependent increases in alkaline phosphatase (ALP), a liver enzyme. This suggests a hepatobiliary response that warrants monitoring over time. The safety data is still limited by small sample sizes (often under 30 dogs) and short study durations.
Behavioral efficacy: overview
Limited and mixed. Three clinical behavioral studies as of the 2023 review; evidence base heterogeneous.
Di Salvo et al. (2023) found only three clinical studies that looked at CBD for behavioral outcomes in dogs — one positive, one mixed, and one negative. That is too small and inconsistent a dataset to draw strong conclusions from. A separate systematic review rated the overall certainty of canine CBD evidence as "very low" due to bias risk, small samples, and inconsistent results. While that review focused on osteoarthritis, the methodological concerns apply broadly to the current state of canine CBD research.
Hunt et al. 2023: acute separation and car-travel stress
Behavioral QBA measures reached significance; subjective sedation-related measures did not.
Hunt et al. (2023) ran a randomized, placebo-controlled study using a single dose of CBD in dogs exposed to separation and car-travel stress. Using Quantitative Behavioral Analysis (QBA), they found statistically significant improvements in stress, tension, and whining in the CBD group. This is a real positive signal in a controlled setting. However, the authors warned against generalizing the result to all CBD products, since factors like bioavailability, formulation, and product quality vary widely between brands.
Flint et al. 2025: 4-arm crossover (n=54)
CBD monotherapy failed to reach significance at either dose; only the combination arm did.
Flint et al. (2025) ran a blinded 4-arm crossover trial with 54 dogs comparing placebo, CBD at 2 mg/kg, CBD at 4 mg/kg, and a combination product (CBD + L-tryptophan + alpha-casozepine) during car travel. Salivary cortisol was the main measure. CBD alone did not significantly reduce cortisol at either dose. Only the combination arm showed a statistically significant effect. The study also found large individual differences in how well dogs absorbed CBD. The combination result is interesting, but it does not support claims that CBD by itself is reliably effective for anxiety.
Rideout et al. 2025: regulatory and quality context
Narrative review. Addresses product quality and regulatory gaps, not behavioral outcomes.
Rideout et al. (2025) reviewed the regulatory and quality landscape for veterinary CBD products. The paper does not contain behavioral efficacy data. Its main value is highlighting a serious quality problem: because there is no pre-market federal regulation, potency and purity vary widely between products. Independent Certificates of Analysis (COAs) are currently the main way to verify what is actually in a bottle.
Key takeaway
Short-term tolerability looks reasonable in existing studies, though dose-dependent ALP elevation is a consistent finding. Behavioral efficacy evidence as of 2025 is limited to: one positive QBA study (Hunt 2023), one 4-arm study where CBD alone failed at both doses and only the combination worked (Flint 2025), and one regulatory/quality review (Rideout 2025). The current evidence base is still too small and inconsistent to support broad efficacy claims for CBD as an anxiety treatment.
Drug interactions and contraindications
CBD is heavily metabolized by the liver, mainly through the cytochrome P450 (CYP450) enzyme system. Because CBD inhibits several CYP450 enzymes, it can increase blood levels of other drugs that are cleared through the same pathways. This is one of the most important safety considerations when a dog is already on other medications.
Hepatic enzyme elevation
Multiple studies have shown that oral CBD causes dose-dependent increases in alkaline phosphatase (ALP). This appears to reflect a liver response (cholestatic stress) rather than outright damage in most cases. Still, any dog on CBD — especially those with existing liver issues or on other hepatically metabolized drugs — should have regular liver panel monitoring.
CYP450-mediated drug interactions
Dogs on medications metabolized by CYP450 enzymes (such as phenobarbital, zonisamide, or many NSAIDs) are at higher risk of drug interactions with CBD. Potassium bromide is an exception because it is excreted by the kidneys rather than the liver. These interactions are well documented in both human and veterinary pharmacology.
Reproductive and developmental exposure
There are currently no reproductive or lactation safety studies for CBD in dogs. We have no data on whether it affects fetal development or passes into milk. Until such data exist, CBD should not be used in pregnant or lactating dogs.
Key takeaway
CBD can inhibit CYP450 enzymes and raise blood levels of other drugs. ALP elevation is a consistent lab finding. There is currently no reproductive safety data in dogs.
Regulatory environment and quality assurance
The regulatory environment for CBD pet products is still fragmented and unsettled. This has major consequences for product quality and consistency.
FDA position
The FDA has not approved any CBD product for veterinary use. The agency's Center for Veterinary Medicine has sent multiple warning letters to companies making unproven therapeutic claims. Because CBD pet products are sold as dietary supplements rather than drugs, they do not go through pre-market safety or efficacy review, bioequivalence testing, or Good Manufacturing Practice requirements.
2018 Farm Bill descheduling and its limits
The 2018 Farm Bill removed hemp from the Controlled Substances Act, but it did not automatically allow CBD in animal products without further regulatory approval. States have created very different rules — some allow CBD in pet products with state oversight, while others restrict or ban it. Veterinary board rules on discussing CBD with clients also vary by state.
Third-party analytical testing (COA)
Because there is no federal pre-market oversight, no government agency verifies that a CBD pet product actually contains the amount of cannabidiol listed on the label or is free from contaminants. Independent testing has repeatedly found products with far less CBD than claimed, as well as heavy metals, pesticides, and sometimes higher-than-allowed THC levels. The main quality tool currently available is a Certificate of Analysis (COA) from an accredited third-party lab. A good COA should confirm the CBD content matches the label, show THC is below 0.3%, and test for heavy metals, pesticides, mycotoxins, and residual solvents.
Extract classification: whole-plant, THC-removed, isolate
Whole-plant extracts keep the full range of cannabinoids and terpenes found in the plant (including minor ones like CBG, CBN, and CBC), along with trace THC under the legal limit. THC-removed versions go through extra processing to eliminate detectable THC while keeping other compounds. Isolate is nearly pure CBD (over 99%) with everything else removed. The idea that whole-plant extracts work better due to "entourage effects" between cannabinoids and terpenes has not been proven in dogs, though it has some support from lab and rodent studies.
Key takeaway
The FDA has not approved CBD for use in dogs. CBD pet products are sold as supplements and do not undergo pre-market safety or efficacy review. The main quality tool available is third-party COA verification.
Comparative evidence: CBD vs. alternative supplements
The limitations of the current CBD behavioral evidence — small samples, CYP450 interactions, regulatory gaps, and the fact that CBD alone failed to reach significance in the most recent major trial — make it worthwhile to look at other supplement categories that work through different mechanisms.
Amino acid and peptide blends
Product-specific evidence; some canine RCT data available. Avoids CYP450 interaction profile.
Formulations with L-theanine (which modulates GABA), L-tryptophan (a serotonin precursor), or alpha-casozepine (a peptide with GABA-A affinity) each have some published canine data. Scandurra et al. (2022) ran a 30-day RCT with 21 dogs using a multi-ingredient blend (krill oil, California poppy, hops, ashwagandha, passionflower, B6, and E). The treated group performed better on a solvable task, and 6 of 42 C-BARQ items improved. Evidence is product-specific, not class-wide. Importantly, the only arm that reached significance in the Flint et al. (2025) study was the one combining CBD with L-tryptophan and alpha-casozepine, suggesting these ingredients may add real value in multi-ingredient products.
Gut-brain axis (probiotics)
Mechanistically plausible; canine behavioral evidence remains preliminary.
Sacoor et al. (2024) reviewed the gut-brain axis in dogs, covering vagus nerve signaling, microbial metabolites, and HPA axis regulation. They concluded that probiotic evidence for reducing anxiety in dogs is still preliminary — mechanistically plausible but not yet well validated in actual canine behavioral studies. This category has the advantage of avoiding cannabinoid-related regulatory and interaction issues.
Behavioral and environmental interventions
Non-supplement approaches with separate evidence bases.
Pressure wraps, synthetic pheromones, environmental enrichment, and structured behavior modification (desensitization + counterconditioning) are non-supplement approaches with their own evidence bases. The literature generally positions supplements as helpful additions to behavioral modification rather than replacements — especially for separation and generalized anxiety. See the dedicated calming supplements guide for a full ingredient-by-ingredient review.
Key takeaway
The fact that only the CBD + L-tryptophan + alpha-casozepine combination reached significance in the Flint et al. (2025) study (while CBD alone did not) suggests the amino acid/peptide ingredients added real value. Other categories such as amino acid blends, probiotics, and behavioral modification have their own evidence and avoid the CYP450 interaction and regulatory issues that come with cannabinoids.
How this guide connects to the Pawsd knowledge base
Pawsd keeps this CBD evidence review in its canine-anxiety reference set. Scout uses its safety limits, study gaps, and product-quality cautions when answering CBD questions for individual dogs. The page is revised when new peer-reviewed veterinary evidence changes that risk-benefit picture.
Frequently asked questions
What does current research conclude about CBD monotherapy for canine anxiety?
As of 2025, CBD by itself has not shown reliable anxiolytic effects in the best-controlled trial to date. Flint et al. (2025) tested 54 dogs in a blinded 4-arm crossover (placebo, CBD 2 mg/kg, CBD 4 mg/kg, and a combination of CBD + L-tryptophan + alpha-casozepine). CBD alone failed to reduce cortisol at either dose. Only the combination arm reached significance (p=0.016). The 2023 Di Salvo review found just three prior behavioral studies in dogs, with mixed results.
What did the Hunt et al. behavioral study actually find?
Hunt et al. (2023) found that Quantitative Behavioral Analysis (QBA) scores for stress, tension, discomfort, sadness, and whining improved significantly with CBD during separation and car-travel stress. This was a real positive signal in a controlled study. However, the authors warned against assuming the same results would apply to all CBD products, since bioavailability, formulation, and actual cannabinoid content vary widely between brands.
How does CBD interact with common canine medications?
CBD primarily inhibits CYP450 enzymes, which are responsible for metabolizing a wide range of co-administered pharmaceuticals. Dogs receiving anticonvulsants (phenobarbital, potassium bromide, zonisamide), NSAIDs, or other CYP450-metabolized drugs face elevated risk of pharmacokinetic interactions. Dose-dependent hepatic ALP elevation has also been documented across multiple canine CBD studies, as summarized by Di Salvo et al. (2023; PMCID: PMC10347378), warranting baseline and serial hepatic monitoring in dogs with pre-existing hepatobiliary disease.
Why is CBD hemp different from hemp-seed products?
Hemp seeds contain negligible concentrations of cannabidiol or other pharmacologically active cannabinoids; CBD is synthesized in the inflorescences and leaves, not the seeds. A product labeled "hemp calming chew" that does not specify cannabidiol content in milligrams per serving is likely a hemp-seed derivative with no meaningful CBD activity — though labels reading "hemp extract," "whole-plant extract," or "THC-removed extract" may still contain cannabinoids and require COA verification. The two product types occupy different regulatory classifications, present different phytochemical profiles, and carry different clinical relevance for anxiolytic applications.
What is the regulatory status of CBD in veterinary products?
The FDA has not approved, conditionally approved, or indexed any CBD product for veterinary use. The 2018 Agriculture Improvement Act descheduled hemp-derived CBD from the Controlled Substances Act but did not authorize its inclusion in dietary supplements or food without separate FDA approval. CBD pet products are sold as dietary supplements, bypassing pre-market safety and efficacy review. State regulatory frameworks vary, and veterinary practice law differs by jurisdiction. The operative federal THC threshold is not more than 0.3 percent delta-9 THC on a dry weight basis.
Evidence-informed article
Pawsd Knowledge articles are educational and not a substitute for veterinary advice. These pages draw from selected open-access peer-reviewed veterinary research, with full-text sources linked below.
Selected references
Di Salvo A, Conti MB, della Rocca G. Front Vet Sci. 2023;10:1204526. PMCID: PMC10347378. Open-access narrative review.
Front Vet Sci. 2023;10:1248417. PMCID: PMC10540436. Open-access systematic review/meta-analysis.
Hunt ABG, Flint HE, Logan DW, King T. Front Vet Sci. 2023;10:1112604. PMCID: PMC9992179. Open-access placebo-controlled study.
Flint HE, Weller JE, Hunt ABG, King T. Front Vet Sci. 2025;12:1632868. PMCID: PMC12339541. Open-access blinded 4-arm crossover (n=54).
Sacoor C, Marugg JD, Empadinhas N, Montezinho L. Vet Med Int. 2024;2024:2856759. PMCID: PMC10827376. Open-access narrative review.
Rideout H, Cook AJC, Whetton AD, et al. J Cannabis Res. 2025;7(1):6. PMCID: PMC11755934. Open-access review of CBD quality assurance and regulatory context for veterinary products.
Related Reading
Acepromazine for Dog Anxiety: Sedation, Fear, and Modern Vet Use
A veterinary-boundary guide to acepromazine for dog anxiety questions, explaining sedation without anxiety relief, noise-fear concerns, historical use, monitoring issues, and modern alternatives.
Dog-Appeasing Pheromone (DAP): Efficacy and Evidence Review
An evidence-based review of dog-appeasing pheromone (DAP) efficacy, vomeronasal processing mechanisms, and clinical limitations in canine behavioral therapy.
Alpha-Casozepine for Dogs: Calming Supplement Evidence and Limits
An evidence-reference guide to alpha-casozepine for dogs, covering proposed GABA-A mechanisms, calming-supplement use, canine evidence limits, combination-product caveats, and when prescription care is more appropriate.
The First Week After Adopting a Dog: Physiological and Behavioral Adjustment
Shelter dogs arrive with elevated physiological stress markers that require time to down-regulate. This guide examines what the research shows about the adjustment arc in newly adopted dogs: the physiological baseline at adoption, the 3-3-3 framework for behavioral adjustment, how schedule predictability reduces arousal, the case for introducing alone time early, and what adopter expectation surveys document about the gap between expected and experienced outcomes.
© 2026 Pawsd LLC. All rights reserved. The selection, arrangement, and original commentary in this guide are the copyrighted work of Pawsd. While the underlying research is publicly available, the editorial analysis, evidence curation, and breed-specific guidance reflect original work. Reproduction or redistribution of this material without written permission is prohibited. For licensing inquiries, contact hello@pawsd.ai.